| Literature DB >> 29251912 |
Stephen A Kelly1, Stefan Pohle2, Scott Wharry2, Stefan Mix2, Christopher C R Allen3, Thomas S Moody2,4, Brendan F Gilmore1.
Abstract
Chiral amines are valuable building blocks for the pharmaceutical industry. ω-TAms have emerged as an exciting option for their synthesis, offering a potential "green alternative" to overcome the drawbacks associated with conventional chemical methods. In this review, we explore the application of ω-TAms for pharmaceutical production. We discuss the diverse array of reactions available involving ω-TAms and process considerations of their use in both kinetic resolution and asymmetric synthesis. With the aid of specific drug intermediates and APIs, we chart the development of ω-TAms using protein engineering and their contribution to elegant one-pot cascades with other enzymes, including carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive overview of their uses, beginning with initial applications through to the present day.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29251912 DOI: 10.1021/acs.chemrev.7b00437
Source DB: PubMed Journal: Chem Rev ISSN: 0009-2665 Impact factor: 60.622